Bausch + Lomb (NYSE:BLCO) Shares Down 5.8% – What’s Next?

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

Head to Head Survey: Bausch + Lomb (NYSE:BLCO) vs. Terumo (OTCMKTS:TRUMY)

Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)